SuppreMol (Germany) early-stage biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases, closed a $25M Series B financing. Participants include MIG, BioMedInvest, Santo Holding, Zetacube, KfW Mittelstandsbank, Bayern Kapital and Max-Planck-Gesellschaft.

Peptimmune (Cambridge, MA) clinical-stage biotechnology company developing peptide and peptide-copolymer therapeutics for the treatment of CNS and Autoimmune disorders, closed a $8.9M Series D financing. Participants include New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical Investors and Silicon Valley Bank Capital.

Merrimack Pharmaceuticals (Cambridge, MA) development-stage biotechnology company focused on novel treatments for autoimmune disease and cancer, closed a $60M Series F financing. Participants include Credit Suisse First Boston, Next Fund, Crocker Ventures, HNI Holdings, Noonday Asset Management, TPG-Axon Capital, and WT Investment Advisors Fund.

AM-Pharma (Netherlands) biopharmaceutical company developing endogenous proteins and peptides to combat acute renal failure, ulcerative colitis and hospital acquired infections, closed a $36M Series C financing. Participants include Forbion Capital Partners and Inventages Venture Capital.

RegImmune (Mountain View, CA) early-stage biopharmaceutical company focused on the treatment of graft versus host disease, allergies, autoimmune diseases and other inflammatory diseases, closed a $8M Series B financing. Participants include NIF SMBC Ventures, CSK Venture Capital, Japan Asia Investment Co, and Yasuda Enterprise Development Co.

ArGentis Pharmaceuticals (Memphis, TN) development-stage biopharmaceutical company focused the development of autoimmunity and ophthalmology therapeutics, closed a $2.0M Series financing. Participants include Innova Memphis.

PeptImmune Inc. (Cambridge, MA) a clinical stage biotechnology company utilizing novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders such as pemphigus vulgaris and multiple sclerosis has closed on the first $8.2M traunche of a Series D financing. Participants include New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical [...]

Proprius Pharmaceuticals (San Diego, CA) a drug developer focused on rheumatology and autoimmune diseases, has raised $11M in Series A funding led by Atlas Venture and joined by Forward Ventures, CDIB BioScience Venture Management along with return backers Fog City Fund and Windamere Venture Partners.